Stockholm - Free Realtime Quote SEK

Sprint Bioscience AB (publ) (SPRINT.ST)

Compare
1.7600 -0.0200 (-1.12%)
As of 4:54 PM GMT+2. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mr. Johan Emilsson Chief Executive Officer 1.68M -- 1984
Prof. P?r Nordlund Founder 25k -- 1958
Dr. Martin Andersson Co-Founder & Chief Scientific Officer -- -- 1971
Dr. Kenth Hallberg Founder & Director of Structural Chemistry -- -- 1971
Mr. Mathias Skalmstad Chief Financial Officer -- -- 1973
Ms. Anne-Marie Wenthzel Chief Business Officer -- -- 1964

Sprint Bioscience AB (publ)

Novum
Floor 8 H?lsov?gen 7 elevator A
Huddinge, 141 57
Sweden
46 84 11 44 55 https://www.sprintbioscience.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
36

Description

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.

Corporate Governance

Sprint Bioscience AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 30, 2024 at 10:59 AM UTC

Sprint Bioscience AB (publ) Earnings Date

Recent Events

Related Tickers